UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934				
(Amendment No. 1)*				
Aura Biosciences, Inc.				
(Name of Issuer)				
Common stock, \$0.00001 par value per share				
(Title of Class of Securities)				
05153U107				
(CUSIP Number)				
September 30, 2024				
(Date of Event Which Requires Filing of this Statement)				
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:				
□ Rule 13d-1(b)				
\square Rule 13d-1(c)				
⊠ Rule 13d-1(d)				
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.				
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).				

CUSIP No. 05153U107

1.	Names of Reporting Persons				
	Lundbeckfond Invest A/S				
2.	Check the Appropriate Box if a Member of a Group (See Instructions)				
	(a) □ (b) ⊠ (1)				
3.	SEC Us	se Only			
4.	Citizens	ship or P	lace of Organization		
	Denmark				
		5.	Sole Voting Power		
			1,750,108 shares		
Numbe Shares		6.	Shared Voting Power		
Benefic	cially				
Owned Each	•	7.	Sole Dispositive Power		
Reporti Person			1,750,108 shares		
1 CISOH WITH		8.	Shared Dispositive Power		
9.	Aggregate Amount Beneficially Owned by Each Reporting Person				
	1,750,108 shares				
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) □				
11.	Percent of Class Represented by Amount in Row (9)				
	3.5% (2)				
12.	Type of Reporting Person (See Instructions)				
	СО				

- (1) All of such shares are Common Stock and held of record by Lundbeckfond. Lene Skole ("Skole") is the Chief Executive Officer of Lundbeckfond and may be deemed to have sole power to vote and dispose of these shares. The directors of Lundbeckfond have delegated voting and dispositive power with respect to the shares held by Lundbeckfond to Skole.
- (2) This calculation is based on 49,606,115 shares of Common Stock outstanding as of August 5, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed on August 8, 2024 with the Securities and Exchange Commission (the "SEC").

CUSIP No. 05153U107

1.	Names of Reporting Persons							
	Lene Skole							
2.	Check the Appropriate Box if a Member of a Group (See Instructions)							
	(a) □ ((b) ⊠ (1)						
3.	SEC Use Only							
4.	Citizenship or Place of Organization							
	Denmark							
5. Sole Voting Power								
Number of			1,750,108 shares					
Shares Benefic		6.	Shared Voting Power 0					
Owned Each	by	7.	Sole Dispositive Power					
Reporti			1,750,108 shares					
Person With		8.	Shared Dispositive Power					
			0					
9.	Aggregate Amount Beneficially Owned by Each Reporting Person							
	1,750,108 shares							
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)							
11.	Percent of Class Represented by Amount in Row (9)							
	3.5% (3)							
12.	Type of Reporting Person (See Instructions)							
	IN							

- (1) All of such shares are Common Stock and held of record by Lundbeckfond. Skole is the Chief Executive Officer of Lundbeckfond and may be deemed to have sole power to vote and dispose of these shares. The directors of Lundbeckfond have delegated voting and dispositive power with respect to the shares held by Lundbeckfond to Skole.
- (2) This calculation is based on 49,606,115 shares of Common Stock outstanding as of August 5, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed on August 8, 2024 with the SEC.

Item 1.

(a) Name of Issuer
Aura Biosciences, Inc. (the "Issuer")

(b) Address of Issuer's Principal Executive Offices 80 Guest Street, Boston, MA 02135

Item 2.

(a) Name of Person Filing Lundbeckfond Invest A/S ("Lundbeckfond") Lene Skole ("Skole")

(b) Address of Principal Business Office or, if none, Residence Scherfigsvej 7 DK-2100, København Ø, Denmark

(c) Citizenship
Entities: Lundbeckfond - Danish corporation
Individuals: Skole - Denmark

(d) Title of Class of Securities
Common Stock, \$0.00001 par value ("Common Stock")

(e) CUSIP Number 05153U107

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable

Item 4. Ownership

The following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 is provided as of September 30, 2024:

		Sole	Shared	Sole	Shared		
Reporting	Shares Held	Voting	Voting	Dispositive	Dispositive	Beneficial	Percentage
Persons	Directly	Power	Power	Power	Power	Ownership	of Class (2)
Lundbeckfond (1)	1,750,108	1,750,108		1,750,108		1,750,108	3.5%
Skole (1)		1,750,108		1,750,108		1,750,108	3.5%

- (1) All of such shares are Common Stock and held of record by Lundbeckfond. Skole is the Chief Executive Officer of Lundbeckfond and may be deemed to have sole power to vote and dispose of these shares. The directors of Lundbeckfond have delegated voting and dispositive power with respect to the shares held by Lundbeckfond to Skole.
- (2) This calculation is based on 49,606,115 shares of Common Stock outstanding as of August 5, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed on August 8, 2024 with the SEC.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following \boxtimes

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Under certain circumstances set forth in the governing documents of Lundbeckfond, the stockholders of Lundbeckfond may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable

Item 8. Identification and Classification of Members of the Group

Not applicable

Item 9. Notice of Dissolution of Group

Not applicable

Item 10. Certification

Not applicable

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.			
Dated: November 14, 2024			
LUNDBECKFOND INVEST A/S			
By: /s/ Christian Elling			
Name: Christian Elling			
Title: Managing Partner			
s/ Lene Skole			
LENE SKOLE, CEO			
ATTENTION			
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).			

6

Exhibit(s):

<u>A</u> <u>Joint Filing Agreement</u>

EXHIBIT A

JOINT FILING AGREEMENT

We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Aura Biosciences, Inc. is filed on behalf of each of us.

LUNDBECKFOND INVEST A/S

By: /s/ Christian Elling	
Name: Christian Elling	
Title: Managing Partner	
/s/ Lene Skole	
LENE SKOLE, CEO	